PRETOMANID
| Brand name | PRETOMANID |
|---|---|
| Active ingredient | PRETOMANID |
| Strength | 200MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | August 2019 |
| Marketing status | RX |
| Code | Expires |
|---|---|
| GAIN | August 2029 |
| ODE-253 | August 2026 |
| NCE | August 2024 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.